Clinicopathological characteristics and treatment outcome in small cell lung cancer: A single institutional experience from India.
Chemotherapy
lung cancer
small cell
Journal
Lung India : official organ of Indian Chest Society
ISSN: 0970-2113
Titre abrégé: Lung India
Pays: India
ID NLM: 8405380
Informations de publication
Date de publication:
Historique:
entrez:
29
2
2020
pubmed:
29
2
2020
medline:
29
2
2020
Statut:
ppublish
Résumé
Small cell lung cancer (SCLC) constitutes 14%-20% of all lung cancers. Clinical data on SCLC are scarce in literature. To report clinical features and treatment outcome of SCLC treated at our center. This is a single institutional data review of SCLC patients treated between June 2011 and December 2018. Patients were staged as either localized or extensive disease after appropriate staging work-up. Patients with localized disease were treated with concurrent chemoradiation with platinum-based chemotherapy. Those with extensive disease were treated with platinum based palliative chemotherapy. Clinicopathological characteristics, treatment details, and outcome were recorded in this study. Patients who received at least one cycle of chemotherapy were included for survival analysis as intent-to-treat analysis. A total of 181 were patients registered with a median age of 62 years (range: 35-86 years) and male: female ratio of 166:15. Eighty-seven percent (n = 157) of patients had smoking history and 15% (n = 28) of patients had symptom of superior vena cava obstruction at baseline. Twenty-seven (15%) patients had localized disease at presentation. One hundred and twenty (66%) patients took systemic chemotherapy. Chemotherapy regimen was carboplatin only in 9 (7%), etoposide-carboplatin in 54 (45%), and cisplatin-etoposide in 57 (48%). Patients received median cycle number of 6 (range: 1-6). Of the evaluable 87 (73%) patients, initial response was complete response in 4, partial response in 57, stable disease in 20, and progressive disease in 6. Twenty patients received second-line chemotherapy at time of disease progression. After a median follow-up of 8.8 months (range: 0.3-46.1), median progression-free survival (PFS) of the whole population was 9.3 months. Small cell carcinoma in our series had a high incidence of advanced stage (85%) and 13% of patients were nonsmoker. Only 66% of patients received palliative chemotherapy and achieved high disease control rate (>75%) in the evaluable patients with median PFS of 9.3 months.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
Small cell lung cancer (SCLC) constitutes 14%-20% of all lung cancers. Clinical data on SCLC are scarce in literature. To report clinical features and treatment outcome of SCLC treated at our center.
MATERIALS AND METHODS
METHODS
This is a single institutional data review of SCLC patients treated between June 2011 and December 2018. Patients were staged as either localized or extensive disease after appropriate staging work-up. Patients with localized disease were treated with concurrent chemoradiation with platinum-based chemotherapy. Those with extensive disease were treated with platinum based palliative chemotherapy. Clinicopathological characteristics, treatment details, and outcome were recorded in this study. Patients who received at least one cycle of chemotherapy were included for survival analysis as intent-to-treat analysis.
RESULTS
RESULTS
A total of 181 were patients registered with a median age of 62 years (range: 35-86 years) and male: female ratio of 166:15. Eighty-seven percent (n = 157) of patients had smoking history and 15% (n = 28) of patients had symptom of superior vena cava obstruction at baseline. Twenty-seven (15%) patients had localized disease at presentation. One hundred and twenty (66%) patients took systemic chemotherapy. Chemotherapy regimen was carboplatin only in 9 (7%), etoposide-carboplatin in 54 (45%), and cisplatin-etoposide in 57 (48%). Patients received median cycle number of 6 (range: 1-6). Of the evaluable 87 (73%) patients, initial response was complete response in 4, partial response in 57, stable disease in 20, and progressive disease in 6. Twenty patients received second-line chemotherapy at time of disease progression. After a median follow-up of 8.8 months (range: 0.3-46.1), median progression-free survival (PFS) of the whole population was 9.3 months.
CONCLUSIONS
CONCLUSIONS
Small cell carcinoma in our series had a high incidence of advanced stage (85%) and 13% of patients were nonsmoker. Only 66% of patients received palliative chemotherapy and achieved high disease control rate (>75%) in the evaluable patients with median PFS of 9.3 months.
Identifiants
pubmed: 32108598
pii: LungIndia_2020_37_2_134_279575
doi: 10.4103/lungindia.lungindia_370_19
pmc: PMC7065549
doi:
Types de publication
Journal Article
Langues
eng
Pagination
134-139Déclaration de conflit d'intérêts
None
Références
J Egypt Natl Canc Inst. 2017 Mar;29(1):47-51
pubmed: 27856126
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
J Clin Oncol. 2012 May 10;30(14):1692-8
pubmed: 22473169
J Thorac Cardiovasc Surg. 2004 Sep;128(3):346-51
pubmed: 15354089
Sultan Qaboos Univ Med J. 2013 Aug;13(3):345-58
pubmed: 23984018
Asian Pac J Cancer Prev. 2013;14(1):489-94
pubmed: 23534779
Thorac Cancer. 2015 May;6(3):233-8
pubmed: 26273367
Clin Oncol (R Coll Radiol). 2002 Oct;14(5):338-51
pubmed: 12555872
Chest. 2007 Sep;132(3 Suppl):324S-339S
pubmed: 17873178
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Lung Cancer. 2011 Mar;71(3):363-6
pubmed: 20619477
BMC Cancer. 2019 Jan 21;19(1):95
pubmed: 30665432
J Glob Oncol. 2017 Jan 11;3(5):459-468
pubmed: 29094084